Detection of HHV-8 DNA in PBMC and Presence of Anti–HHV-8 Antibodies in Sera of Patients With KS or at Risk of KS
| Patients . | No. of Patients . | Positive/Analyzed Patients (%) . | |||
|---|---|---|---|---|---|
| HHV-8 DNA (PCR) . | 95% CI . | Anti–HHV-8 Antibodies (IFA) . | 95% CI . | ||
| KS | |||||
| AIDS-KS | 32 | 22/32 (69%) | 50-83.8 | 17/17 (100%) | 80.5-100 |
| CKS | 11 | 6/11 (54%) | 23.4-83.6 | 11/11 (100%) | 71.5-100 |
| PT-KS | 2 | 1/2 (50%) | 1.3-98.7 | 2/2 (100%) | 15.8-100 |
| Total | 45 | 29/45 (64%) | 48.8-78.1 | 30/30 (100%) | 88.4-100 |
| At risk of KS | |||||
| NKS-AIDS | 25 | 2/25 (8%) | 1.0-26.0 | 6/12 (50%) | 21.1-78.9 |
| HIV+ | 7 | 0/7 (0%) | 0-40.1 | 5/7 (71%) | 29.0-96.3 |
| PT | 13 | 2/13 (15%) | 1.9-45.4 | 6/10 (60%) | 26.2-87.8 |
| Total | 45 | 4/45 (9%) | 2.5-21.2 | 17/29 (59%) | 38.9-76.5 |
| Patients . | No. of Patients . | Positive/Analyzed Patients (%) . | |||
|---|---|---|---|---|---|
| HHV-8 DNA (PCR) . | 95% CI . | Anti–HHV-8 Antibodies (IFA) . | 95% CI . | ||
| KS | |||||
| AIDS-KS | 32 | 22/32 (69%) | 50-83.8 | 17/17 (100%) | 80.5-100 |
| CKS | 11 | 6/11 (54%) | 23.4-83.6 | 11/11 (100%) | 71.5-100 |
| PT-KS | 2 | 1/2 (50%) | 1.3-98.7 | 2/2 (100%) | 15.8-100 |
| Total | 45 | 29/45 (64%) | 48.8-78.1 | 30/30 (100%) | 88.4-100 |
| At risk of KS | |||||
| NKS-AIDS | 25 | 2/25 (8%) | 1.0-26.0 | 6/12 (50%) | 21.1-78.9 |
| HIV+ | 7 | 0/7 (0%) | 0-40.1 | 5/7 (71%) | 29.0-96.3 |
| PT | 13 | 2/13 (15%) | 1.9-45.4 | 6/10 (60%) | 26.2-87.8 |
| Total | 45 | 4/45 (9%) | 2.5-21.2 | 17/29 (59%) | 38.9-76.5 |
Freshly isolated PBMC were analyzed for HHV-8 DNA by PCR and sera for anti–HHV-8 antibodies by IFA. 95% CI are shown. Patients with KS show a higher prevalence of both viral DNA and antibodies as compared with patients at risk of KS (test on equality of proportions;P < .001).